Detection

Lumicell Introduces Further Research and Insights in Fluorescence-Guided Surgery at the Society of Surgical Oncology (SSO) Annual Meeting

Retrieved on: 
Monday, March 25, 2024
Health, Surgery, Oncology, Medical Devices, Breast cancer, Feasibility, Detection, DVS, Massachusetts General Hospital, Light, Inc., Patient, Neoplasm, Stanford University Medical Center, NDA, University, Doctor of Philosophy, Society, Surgeon, Patient satisfaction, Surgical oncology, SSO, Hospital, PMA, Multimedia, MD Anderson Cancer Center, FDA, Associate professor, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20240325761901/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240325761901/en/
    Barbara Smith, M.D, PhD., presented results from the INSITE study during the Breast Cancer Hub Zone talk during the SSO Annual Meeting 2024.
  • “It’s so energizing to see such a diversity of surgeons across different specialties come together to advance the collective field of surgical oncology,” said Jorge Ferrer, M.D., PhD, Chief Scientific Officer, Lumicell.
  • Most recently, the FDA’s Medical Imaging Drugs Advisory Committee (MIDAC) voted in support of the benefit-risk profile of LUMISIGHT™ (pegulicianine) during its March 5, 2024 meeting .
  • The FDA is expected to make a decision on Lumicell’s NDA and PMA in the near future.

Securing the Future Together: FluidOne and its Cyber Security Associates Division (CSA) Acquire SureCloud Cyber Services to Bolster Their Expertise Aimed at Keeping Customers Safe.

Retrieved on: 
Wednesday, March 13, 2024
Online Privacy, Technology, Security, Consulting, Professional Services, Software, Networks, Internet, Data Management, IOT (Internet of Things), Cloud, Sentinel, MOD, Microsoft, NCSC, CSA, Culture, Detection, Growth, Payment card industry, Acquisition, MD, CNC, Commercial director, PCI, MSP, Public sector, CREST, Multimedia, NCC, Computer security, Feedback, Management

The acquisition will enable CSA to enhance its services and provide its customers with a more comprehensive range of cyber security solutions against the ever-growing cyber threat.

Key Points: 
  • The acquisition will enable CSA to enhance its services and provide its customers with a more comprehensive range of cyber security solutions against the ever-growing cyber threat.
  • View the full release here: https://www.businesswire.com/news/home/20240313036120/en/
    Cyber Security Associates, a division of FluidOne, acquires penetration testing specialist SureCloud Cyber Services.
  • FluidOne invested in CSA in 2020 as a Centre of Excellence for cyber security following market demand for expertise to protect customers from the growing threat landscape.
  • The SureCloud Cyber Services portfolio perfectly complements that offered by CSA and the acquisition will benefit both businesses clients.

Nuspire Enhances Managed Security Offerings with Dark Web Monitoring Integration

Retrieved on: 
Thursday, April 4, 2024
Dark, MSSP, Organization, Detection, Environment, Intelligence, Risk, Internet, Nature, Fraud, Risk management

COMMERCE, Mich., April 4, 2024 /PRNewswire/ -- Nuspire, a leading managed security services provider (MSSP), today announced that it has added Dark Web Monitoring to its portfolio of services and solutions. By integrating Dark Web Monitoring with Nuspire's detection and response services, the new offering fortifies the existing managed security suite with a dual-layered defense strategy, effectively safeguarding client environments against both external intrusions and internal vulnerabilities.

Key Points: 
  • COMMERCE, Mich., April 4, 2024 /PRNewswire/ -- Nuspire, a leading managed security services provider (MSSP), today announced that it has added Dark Web Monitoring to its portfolio of services and solutions.
  • By integrating Dark Web Monitoring with Nuspire's detection and response services, the new offering fortifies the existing managed security suite with a dual-layered defense strategy, effectively safeguarding client environments against both external intrusions and internal vulnerabilities.
  • Nuspire's Dark Web Monitoring service addresses these challenges by providing cybersecurity teams with actionable intelligence, enhancing both internal and external threat detection capabilities.
  • Dark Web Monitoring can integrate with any of Nuspire's managed security services or can be used as a stand-alone service, and provides:
    Continuous Dark Web Monitoring: Includes constant surveillance of the dark web to identify emerging threats.

NetSPI Achieves Prestigious CBEST Accreditation, Solidifying Its Position as a Trusted Leader in Financial Services Security Testing

Retrieved on: 
Tuesday, April 2, 2024
CBEST, Professional, Detection, Bank, Accreditation, Customer, Fortune 500, TIBER, Asset, CSP, Threat

LONDON, April 2, 2024 /PRNewswire/ -- NetSPI, the proactive security solution, has announced its achievement of CBEST accreditation, marking a significant milestone in its commitment to delivering high-value penetration testing and red teaming services. CBEST, set by the Bank of England, represents one of the most rigorous security standards in the financial services industry. NetSPI's accreditation places it among the top echelons of security testing organisations across the globe.

Key Points: 
  • CBEST, set by the Bank of England, represents one of the most rigorous security standards in the financial services industry.
  • NetSPI's accreditation places it among the top echelons of security testing organisations across the globe.
  • NetSPI's success in this accreditation underscores its dedication to maintaining the highest standards of security testing and validation.
  • "Securing CBEST accreditation is a testament to NetSPI's unwavering commitment to excellence in cybersecurity," says Nick Walker, Regional Leader of EMEA at NetSPI.

Adela to Present Data from Tissue-Agnostic MRD Assay at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Tuesday, March 19, 2024
Princess Margaret Cancer Centre, Detection, Interception, Nucleic acid thermodynamics, AACR, MRD, Sinai Health System, Biology, University Health Network

FOSTER CITY, Calif., March 19, 2024 /PRNewswire/ -- Adela, Inc., an innovator in blood testing for minimal residual disease monitoring and early cancer detection through a proprietary genome-wide methylome enrichment technology, today announced data will be presented at the American Association for Cancer Research (AACR) Annual Meeting from April 5-10, 2024 from its tissue-agnostic minimal residual disease (MRD) assay. These data demonstrate the feasibility of the assay for cfDNA cancer signal quantification and prognostic prediction in HPV-positive and HPV-negative head & neck cancers following treatment. Data will also be presented on the analytical performance of Adela's platform.

Key Points: 
  • These data demonstrate the feasibility of the assay for cfDNA cancer signal quantification and prognostic prediction in HPV-positive and HPV-negative head & neck cancers following treatment.
  • Dr. De Carvalho will also present in the session "New Liquid Biopsy Technologies for Detection and Characterization of Cancer".
  • Adela plans to commercialize its first product, a tissue agnostic test for minimal residual disease (MRD) monitoring, in 2025.
  • It can be applied across the entire cancer care continuum and is initially being developed for MRD and multi-cancer early detection.

Molecular Devices Appoints Mary Duseau as President, Bringing 25 Years of Experience in Life Sciences

Retrieved on: 
Wednesday, March 13, 2024
Health, Detection, Communication, PerkinElmer, Danaher Corporation, SAN, Leica Biosystems, University, Senior, Biology, Marketing, Molecular Devices, DHR, Pharmaceutical industry

SAN JOSE, Calif., March 13, 2024 /PRNewswire-PRWeb/ -- Molecular Devices, LLC., a leading high-performance life science solutions provider and an operating company in the life sciences segment of Danaher Corporation (NYSE:DHR), today announced Mary Duseau's appointment as its new president, succeeding interim president, Greg Milosevich.

Key Points: 
  • , a leading high-performance life science solutions provider and an operating company in the life sciences segment of Danaher Corporation (NYSE:DHR), today announced Mary Duseau's appointment as its new president, succeeding interim president, Greg Milosevich.
  • "Mary brings more than 25 years of life science experience and a track record of achieving exceptional business results to Molecular Devices," said Greg Milosevich, Vice President, and Group Executive Life Sciences Innovations Group at Danaher Corporation.
  • Prior to joining Molecular Devices, Mary spent six years at Leica Biosystems, also a Danaher operating company.
  • "In this short time as president, it's clear that Molecular Devices' innovative technology and diverse team are enabling a revolution of human health – and that's really inspiring," said Mary Duseau, President of Molecular Devices.

Todyl Raises $50M in Series B Funding

Retrieved on: 
Thursday, March 7, 2024
Data Management, Security, Technology, Other Technology, Software, Networks, Internet, Engineering, SMB, Palo Alto Networks, Detection, CrowdStrike, TechOperators, GRC, Investment, SOAR, Endpoint security, Secure access service edge, Venture round, Automation, SIEM, Knowledge, Former, Microsoft, Risk management

Todyl, an industry-leading security and networking company, announced today it closed a $50 Million Series B investment round led by Base10 Partners with participation from Anthos Capital, Tech Operators, and StoneMill Ventures.

Key Points: 
  • Todyl, an industry-leading security and networking company, announced today it closed a $50 Million Series B investment round led by Base10 Partners with participation from Anthos Capital, Tech Operators, and StoneMill Ventures.
  • The Series B funding will support Todyl’s mission of revolutionizing cybersecurity with an all-in-one security platform that empowers IT professionals with the tools, insights, and automation needed to defend against ever-changing threats.
  • With the addition of SOAR, Todyl further empowers businesses to execute rapid, automated response actions across endpoints and Microsoft 365.
  • “Todyl has demonstrated that it is becoming a meaningful and serious alternative to some of the incumbents in the space.

Balluff Adds Blue Light and Time-of-Flight Photoelectric Sensors

Retrieved on: 
Friday, March 8, 2024
Dark, Detection, Communication, Family

FLORENCE, Ky., March 8, 2024 /PRNewswire-PRWeb/ -- Blue lights and time-of-flight technology add a new level of versatility to Balluff's already robust photoelectric family.

Key Points: 
  • Balluff's blue light and time-of-flight photoelectric sensors share many common features, including their small cubical housing, operating concept, and IO-Link communication.
  • Blue light sensing for background suppression is ideal for reliably detecting transparent, dark, or shiny objects.
  • Blue light has a shorter wavelength than other colors of visible light, so it scatters less, and the light beam is better focused to detect finer details.
  • In addition, blue light penetrates less deeply into materials than other light wavelengths.

FTC announces challenge to prevent harms of AI-enabled voice cloning

Retrieved on: 
Thursday, February 15, 2024
Internet, Knowledge, Detection, America COMPETES Act, FTC, Human voice, Evaluation, Human, Music, AI, Intelligence, Mobile phone

The prospects could be promising, but from the FTC’s perspective, voice cloning also presents serious consumer protection concerns.

Key Points: 
  • The prospects could be promising, but from the FTC’s perspective, voice cloning also presents serious consumer protection concerns.
  • The FTC is committed to using a wide range of tools to prevent harm to the public.
  • That’s the reason for the just-announced Voice Cloning Challenge.
  • Read the FTC Voice Cloning Challenge page for more information about participating.

Cleerly® Announces CERTAIN Multicenter Clinical Trial Results

Retrieved on: 
Thursday, February 8, 2024
Health, Clinical Trials, Cardiology, Other Health, Drug, Ischemia, MD, American College, Derivation, Cole, Detection, Medicine, Intelligence, Artificial intelligence, Coronary ischemia, Science, Atherosclerosis, Society, CCTA, Myocardial perfusion imaging, PMID, Plaque, SPECT, PET, FDA, Adenosine, American Journal of Roentgenology, Diagnosis, Patient, Stenosis, Moyamoya disease, Validation, Splenic infarction, Physician, Health literacy, Journal, Coronary artery disease, Coronary, Medical imaging

These results underscore the strong and positive effect of the Cleerly products on clinical utility for patients with suspected coronary artery disease.

Key Points: 
  • These results underscore the strong and positive effect of the Cleerly products on clinical utility for patients with suspected coronary artery disease.
  • In all multicenter and single clinical studies performed to date, Cleerly’s products have consistently demonstrated robust clinical utility, including higher diagnostic accuracy and stronger prognostic risk stratification over such historical tests as nuclear SPECT stress testing and FFRCT2-7.
  • Cleerly’s approach is grounded in science, based on over 10 million images from over 40,000 patients gathered over a 15-year-period in landmark, multi-center clinical trials.
  • Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway.